Pusan National University Hospital
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1956-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- https://www.pnuh.or.kr
Korean AML drug shows 50% overall complete response rate in P1 trial
In a phase 1 study of PHI-101 for AML, 50% of evaluable patients achieved an overall complete response. PHI-101 targets FLT3 gene mutation in AML patients, presenting at ASH 2024. Pharos iBio plans to complete phase 1 and proceed with early commercialization.
© Copyright 2024. All Rights Reserved by MedPath